Glypressin

Glypressin is an injectable solution containing the vasopressin analog terlipressin acetate. It is supplied in a sterile liquid form for intravenous administration and is marketed in the European Union as a prescription‑only medication. As a V1‑receptor agonist, Glypressin produces vasoconstriction that lowers portal venous pressure, making it useful in managing certain bleeding and circulatory conditions. It is typically stored at controlled room temperature and protected from light.

Glypressin is indicated for specific clinical situations where rapid reduction of portal pressure or control of bleeding is required.

- Management of acute esophageal variceal bleeding in patients with portal hypertension. - Adjunctive therapy to lower portal venous pressure in cirrhotic patients undergoing endoscopic procedures. - Treatment of severe portal hypertension when conventional measures are insufficient. - Off‑label use in selected cases of hepatorenal syndrome to improve renal perfusion. - Supportive measure in the control of bleeding from gastric varices.

The safety profile of Glypressin reflects its vasoconstrictive activity, with side effects ranging from mild to potentially serious.

Common: - Transient headache or facial flushing, typically resolving within a few hours after the dose. - Nausea, abdominal discomfort, or mild vomiting that may improve with supportive care. - Elevated blood pressure or tachycardia observed during infusion, often manageable by dose adjustment. - Peripheral ischemia presenting as cold extremities or mild discoloration without tissue loss.

Serious: - Severe hypertension or hypertensive crisis requiring immediate antihypertensive therapy. - Cardiac arrhythmias, including atrial fibrillation or ventricular ectopy, that may need cardiac monitoring. - Ischemic complications such as myocardial infarction or limb gangrene associated with profound vasoconstriction. - Acute respiratory distress or pulmonary edema demanding urgent medical intervention.

When prescribing Glypressin, clinicians should evaluate patient-specific factors and monitor for potential complications.

- Use caution in patients with pre‑existing cardiovascular disease, including coronary artery disease or heart failure. - Avoid rapid infusion rates; administer according to recommended infusion protocols to reduce risk of hypertension. - Monitor blood pressure and heart rate continuously during and after administration. - Assess renal function before use, especially in patients with acute kidney injury or chronic renal impairment. - Contraindicated in individuals with known hypersensitivity to terlipressin or any component of the formulation. - Pregnancy and lactation status should be considered, as safety data are limited.

Glypressin may interact with other agents that affect vascular tone, cardiac rhythm, or renal function, requiring careful management.

Avoid: - Concomitant use of other potent vasoconstrictors (e.g., norepinephrine, phenylephrine) that could exacerbate hypertension. - Strong CYP3A4 inducers that may alter terlipressin metabolism, although metabolic pathways are not fully defined.

Use with caution: - Beta‑blockers, which may mask tachycardia while hypertension persists. - Diuretics, especially loop diuretics, that can affect intravascular volume and renal perfusion. - Anticoagulants or antiplatelet agents, as changes in portal pressure may influence bleeding risk. - Drugs that prolong QT interval, given the potential for arrhythmias.